Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancer Cell|September 30, 2022
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsAmin H Nassar, Elio Adib, Sarah Abou Alaiwi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung CancerArielle Elkrief, Meagan Montesion, Smruthy Sivakumar, et al.Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitorsAlessandro Di Federico, Lingzhi Hong, Arielle Elkrief, et al.Nature|November 10, 2022
Non-viral precision T cell receptor replacement for personalized cell therapySusan P Foy, Kyle Jacoby, Daniela A Bota, et al.JAMA Oncology|November 3, 2022
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19Ziad Bakouny, Chris Labaki, Punita Grover, et al.Cancer Cell|March 27, 2026
Cancer type-specific variation in patterns of driver alterations across 50,000 tumorsChaitanya Bandlamudi, Daniel Muldoon, Ino de Bruijn, et al.Pageof 7